Cargando…

Demyelination in multiple sclerosis

This review, focused on demyelination in multiple sclerosis, is divided in two parts. The first part addresses the many and not exclusive mechanisms leading to demyelination in the central nervous system. Although the hypothesis that a primary oligodendrocyte or myelin injury induces a secondary imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lubetzki, Catherine, Stankoff, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152443/
https://www.ncbi.nlm.nih.gov/pubmed/24507514
http://dx.doi.org/10.1016/B978-0-444-52001-2.00004-2
_version_ 1783521480893530112
author Lubetzki, Catherine
Stankoff, Bruno
author_facet Lubetzki, Catherine
Stankoff, Bruno
author_sort Lubetzki, Catherine
collection PubMed
description This review, focused on demyelination in multiple sclerosis, is divided in two parts. The first part addresses the many and not exclusive mechanisms leading to demyelination in the central nervous system. Although the hypothesis that a primary oligodendrocyte or myelin injury induces a secondary immune response in the central nervous system is still a matter of debate, most recent advances underline the influence of a primary immune response against myelin antigen(s), with a diversity of potential targets. Whereas multiple sclerosis was long considered as a T cell-mediated disease, the role of B lymphocytes is now increasingly recognized, and the influence of antibodies on tissue damage actively investigated. The second part of the review describes the axonal consequences of demyelination. Segmental demyelination results in conduction block or slowing of conduction through adaptative responses, notably related to modifications in the distribution of voltage gated sodium channels along the denuded axon. If demyelination persists, these changes, as well as the loss of trophic and metabolic support, will lead to irreversible axonal damage and loss. In this respect, favouring early myelin repair, during a window of time when axonal damage is still reversible, might pave the way for neuroprotection.
format Online
Article
Text
id pubmed-7152443
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71524432020-04-13 Demyelination in multiple sclerosis Lubetzki, Catherine Stankoff, Bruno Handb Clin Neurol Article This review, focused on demyelination in multiple sclerosis, is divided in two parts. The first part addresses the many and not exclusive mechanisms leading to demyelination in the central nervous system. Although the hypothesis that a primary oligodendrocyte or myelin injury induces a secondary immune response in the central nervous system is still a matter of debate, most recent advances underline the influence of a primary immune response against myelin antigen(s), with a diversity of potential targets. Whereas multiple sclerosis was long considered as a T cell-mediated disease, the role of B lymphocytes is now increasingly recognized, and the influence of antibodies on tissue damage actively investigated. The second part of the review describes the axonal consequences of demyelination. Segmental demyelination results in conduction block or slowing of conduction through adaptative responses, notably related to modifications in the distribution of voltage gated sodium channels along the denuded axon. If demyelination persists, these changes, as well as the loss of trophic and metabolic support, will lead to irreversible axonal damage and loss. In this respect, favouring early myelin repair, during a window of time when axonal damage is still reversible, might pave the way for neuroprotection. Elsevier B.V. 2014 2014-02-05 /pmc/articles/PMC7152443/ /pubmed/24507514 http://dx.doi.org/10.1016/B978-0-444-52001-2.00004-2 Text en Copyright © 2014 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lubetzki, Catherine
Stankoff, Bruno
Demyelination in multiple sclerosis
title Demyelination in multiple sclerosis
title_full Demyelination in multiple sclerosis
title_fullStr Demyelination in multiple sclerosis
title_full_unstemmed Demyelination in multiple sclerosis
title_short Demyelination in multiple sclerosis
title_sort demyelination in multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152443/
https://www.ncbi.nlm.nih.gov/pubmed/24507514
http://dx.doi.org/10.1016/B978-0-444-52001-2.00004-2
work_keys_str_mv AT lubetzkicatherine demyelinationinmultiplesclerosis
AT stankoffbruno demyelinationinmultiplesclerosis